# Single Dose Pharmacokinetic (PK) Study

> **NCT03109756** · PHASE1 · COMPLETED · sponsor: **Healx AI** · enrollment: 12 (actual)

## Conditions studied

- Angelman Syndrome
- Fragile X Syndrome

## Interventions

- **DRUG:** OV101

## Key facts

- **NCT ID:** NCT03109756
- **Lead sponsor:** Healx AI
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-03
- **Primary completion:** 2017-11-28
- **Final completion:** 2017-11-28
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2017-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03109756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03109756, "Single Dose Pharmacokinetic (PK) Study". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03109756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*